ABIVAX: ABX464 shows excellent long-term efficacy data in Abivax’s phase 2b maintenance Trial in ulcerative colitis
Impressive clinical remission in 58.4% (ITT) of 101 patients after 48 weeks of once-daily oral 50mg ABX464, showing both maintained...